Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neuroendocrine Tumors (pNET) 1Oropharyngeal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anus Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anal Canal Carcinoma 1

Interventions

Specimen Handling 2ribociclib 1pembrolizumab 1exemestane 1durvalumab 1Watchful Waiting 1Taxes 1Paclitaxel 1Observation 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Watchful Waiting × 30 days × Clear all
NCT05812807 2026-06-05

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
1,295 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡